Clinical Summary
Clinical Summary: Identifying Optimal Thresholds for Early Opioid Use Frequency in Predicting Buprenorphine Outcomes
Many patients starting buprenorphine continue using opioids in the first few weeks, but clinicians have had little guidance on how much early use should trigger concern. This study identifies practical early-use thresholds that help flag patients at higher risk for sustained opioid use, fewer opioid-free weeks, and earlier dropout from treatment.
Design
secondary analyses of 2 randomized clinical trials (RCTs) of buprenorphine treatment
N
N=562
Population
participants (N=360) were adults with DSM-IV prescription opioid dependence9 enrolled in POATS.2 In phase 2 data (N=360). Participants in Study 2 (N=202; enrolled in 2007–2011) were adults who met criteria for DSM-IV-TR10 opioid dependence (59% with primary heroin use).
Setting
we examined the first 12 weeks (following the 2-week induction for Study 2) to facilitate harmonization
Key Findings
- The optimal threshold for early nonresponse in weeks 1–2 was ≥1 day of opioid use (out of 14 days); this threshold had sensitivity 0.747, specificity 0.688, positive predictive value 52%, and negative predictive value 86% for later sustained opioid use.
- The optimal threshold for early nonresponse in weeks 1–3 was ≥2 days (out of 21 days); this threshold had sensitivity 0.649, specificity 0.810, positive predictive value 61%, and negative predictive value 83% for later sustained opioid use.
- Early nonresponse in weeks 1–2 was associated with 6.43 times greater odds of sustained opioid use in weeks 5–12, approximately 3.12 fewer opioid-free weeks, and 1.11 fewer weeks retained in treatment.
- Using the weeks 1–3 threshold, early nonresponse was associated with 7.54 times greater odds of returning to sustained use, approximately 3.70 fewer opioid-free weeks, and 1.46 fewer weeks retained in treatment.
- In the descriptive results, 52% of individuals reporting any opioid use in the first 2 weeks went on to sustained use versus 14% who were abstinent, while 61% of individuals with 2 or more days of use in the first 3 weeks reported sustained use versus 17% with 1 or no days.
Clinical Bottom Line
Any illicit opioid use in the first 2 weeks of buprenorphine treatment, or more than 1 day of use in the first 3 weeks, marks a clinically meaningful increase in risk for poor short-term outcomes. These thresholds are simple enough to use in routine follow-up and should prompt closer monitoring and treatment adjustment.
Practice Implications
- Ask about opioid use frequency at least weekly during the first 3 weeks; even 1 day of use in weeks 1–2 met the early nonresponse threshold.
- Use the weeks 1–2 threshold (sensitivity 0.747) when the goal is to capture a broader at-risk group for lower-burden interventions such as closer follow-up or buprenorphine dose adjustment.
- Use the weeks 1–3 threshold (specificity 0.810) when deciding on more intensive or resource-heavy responses, because it more precisely identifies patients at higher risk for sustained opioid use.
- When early nonresponse is present, consider treatment adjustments grounded in the article, including increased dose, switching formulations, adjunctive behavioral treatment, harm-reduction counseling, and targeted efforts to improve retention.
